These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28455651)

  • 1. [Management of hemorrhage in patients treated with direct oral anticoagulants].
    Grottke O; Lier H; Hofer S
    Anaesthesist; 2017 Sep; 66(9):679-689. PubMed ID: 28455651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Direct oral anticoagulant associated bleeding].
    Godier A; Martin AC; Rosencher N; Susen S
    J Mal Vasc; 2016 Jul; 41(4):272-8. PubMed ID: 27297642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants (DOAC) - Management of emergency situations.
    Lindhoff-Last E
    Hamostaseologie; 2017; 37(4):257-266. PubMed ID: 29582928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific antidotes in development for reversal of novel anticoagulants: a review.
    Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
    Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z
    Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anticoagulation-direct oral anticoagulants].
    Kemkes-Matthes B
    Internist (Berl); 2017 Jun; 58(6):585-597. PubMed ID: 28536761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
    Darius H
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to effectively manage the event of bleeding complications when using anticoagulants.
    Sartori MT; Prandoni P
    Expert Rev Hematol; 2016 Jan; 9(1):37-50. PubMed ID: 26573697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversal strategies for non-vitamin K antagonist oral anticoagulants].
    Larsen FU; Hvas AM; Grove EL
    Ugeskr Laeger; 2016 Oct; 178(40):. PubMed ID: 27697119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants.
    Summers RL; Sterling SA
    Air Med J; 2016; 35(3):148-55. PubMed ID: 27255877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
    Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
    Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First NOAk specific antidote as additional safety factor in therapy].
    MMW Fortschr Med; 2016 Feb; 158(2):66-7. PubMed ID: 27017635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.